Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

BACKGROUND: Ipilimumab and vemurafenib have both been shown to improve survival in phase III trials of patients with metastatic melanoma. Although vemurafenib is associated with a rapid onset of activity, responses are often of limited duration. Conversely, responses to ipilimumab take time to devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A, Simeone, Ester, Giannarelli, Diana, Grimaldi, Antonio M, Romano, Anna, Mozzillo, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464706/
https://www.ncbi.nlm.nih.gov/pubmed/22640478
http://dx.doi.org/10.1186/1479-5876-10-107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464706/
https://www.ncbi.nlm.nih.gov/pubmed/22640478
http://dx.doi.org/10.1186/1479-5876-10-107

Ejemplares similares